Optimising Chronic Myeloid Leukaemia Therapy in the Face of Resistance to Tyrosine Kinase Inhibitors – A Synthesis of Clinical and Laboratory Data
Optimizing CML Therapy Despite Resistance to Tyrosine Kinase Inhibitors
DA Irvine, NB Heaney, TL Holyoake
Yes
20100001
2010 Jan 1
Blood Rev
Optimising Chronic Myeloid Leukaemia Therapy in the Face of Resistance to Tyrosine Kinase Inhibitors – A Synthesis of Clinical and Laboratory Data
Blood Rev. 2010 Jan 1;24(1):1-9, DA Irvine, NB Heaney, TL Holyoake
Abstract
Abstract
Imatinib dose escalation, use of another TKI, or allogeneic stem cell transplant are options for overcoming imatinib resistance.
